FDA chief backs 2 new pathways to spur drug importation — but analysts shrug it all off
HHS chief Alex Azar has rolled out a plan to spur the importation of cheaper overseas drugs — including Canada — and he has recruited acting FDA chief Ned Sharpless as an advocate who will help make it happen.
Azar announced Wednesday that the Trump administration is posting a notice of proposed rulemaking that will authorize states, drug wholesalers and manufacturers to launch pilot importation projects out of Canada with the help of HHS.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 77,000+ biopharma pros reading Endpoints daily — and it's free.